Complete Response to Pembrolizumab in a Patient with Castration-Resistant Prostate Cancer with Both BRCA Positivity and a High Frequency of Microsatellite Instability: A Case Report.

IF 0.7 Q4 ONCOLOGY
Case Reports in Oncology Pub Date : 2024-08-05 eCollection Date: 2024-01-01 DOI:10.1159/000540419
Takayuki Hirano, Kousuke Yonezawa, Takashi Kawahara, Nobuhiko Mizuno, Hiroyuki Hayashi, Yuta Karibe, Jun Asano, Shusei Fusayasu, Kazuhide Makiyama, Hiroji Uemura, Junichi Ohta, Masatoshi Moriyama
{"title":"Complete Response to Pembrolizumab in a Patient with Castration-Resistant Prostate Cancer with Both BRCA Positivity and a High Frequency of Microsatellite Instability: A Case Report.","authors":"Takayuki Hirano, Kousuke Yonezawa, Takashi Kawahara, Nobuhiko Mizuno, Hiroyuki Hayashi, Yuta Karibe, Jun Asano, Shusei Fusayasu, Kazuhide Makiyama, Hiroji Uemura, Junichi Ohta, Masatoshi Moriyama","doi":"10.1159/000540419","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>There have been few reports of patients for whom a cancer gene panel test for solid tumors revealed the simultaneous presence of BRCA mutation and microsatellite instability (MSI)-high status. BRCA mutations have been reported in 13% of castration-resistant prostate cancer (CRPC) patients, and 3.1% of prostate cancer cases are MSI-high/mismatch repair deficient.</p><p><strong>Case presentation: </strong>A 71-year-old man with a history of urinary retention was referred to our department for clinically suspected prostate cancer and a high prostate-specific antigen (PSA) level (141 ng/mL). MRI revealed features of prostate cancer invading the bladder, seminal vesicles, and rectum. A histopathological examination of a transperineal needle biopsy specimen obtained from the prostate revealed adenocarcinoma. Bone scintigraphy revealed multiple metastases. The patient was treated with abiraterone acetate combined with androgen deprivation therapy followed by local radiation. Rectal wall thickening and lymph node metastasis were also observed, and docetaxel was administered. A cancer gene panel test was positive results for BRCA2 mutation with a MSI-high. After six courses of docetaxel, lymph node enlargement was observed and olaparib was initiated. Two months later, the metastatic lesions showed enlargement and the PSA level increased. Subsequently, pembrolizumab was administered. At 2 to the patient months after the initiation of pembrolizumab administration, PSA levels decreased to <0.025 ng/mL and the rectal lesions and lymph node metastases disappeared. The patient was continuing to receive pembrolizumab without any apparent adverse events or exacerbations, 9 months after initiation.</p><p><strong>Conclusion: </strong>We herein report a case in which pembrolizumab treatment resulted in a complete response in a CRPC patient with both a BRCA2 mutation and an MSI-high status.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324272/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000540419","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: There have been few reports of patients for whom a cancer gene panel test for solid tumors revealed the simultaneous presence of BRCA mutation and microsatellite instability (MSI)-high status. BRCA mutations have been reported in 13% of castration-resistant prostate cancer (CRPC) patients, and 3.1% of prostate cancer cases are MSI-high/mismatch repair deficient.

Case presentation: A 71-year-old man with a history of urinary retention was referred to our department for clinically suspected prostate cancer and a high prostate-specific antigen (PSA) level (141 ng/mL). MRI revealed features of prostate cancer invading the bladder, seminal vesicles, and rectum. A histopathological examination of a transperineal needle biopsy specimen obtained from the prostate revealed adenocarcinoma. Bone scintigraphy revealed multiple metastases. The patient was treated with abiraterone acetate combined with androgen deprivation therapy followed by local radiation. Rectal wall thickening and lymph node metastasis were also observed, and docetaxel was administered. A cancer gene panel test was positive results for BRCA2 mutation with a MSI-high. After six courses of docetaxel, lymph node enlargement was observed and olaparib was initiated. Two months later, the metastatic lesions showed enlargement and the PSA level increased. Subsequently, pembrolizumab was administered. At 2 to the patient months after the initiation of pembrolizumab administration, PSA levels decreased to <0.025 ng/mL and the rectal lesions and lymph node metastases disappeared. The patient was continuing to receive pembrolizumab without any apparent adverse events or exacerbations, 9 months after initiation.

Conclusion: We herein report a case in which pembrolizumab treatment resulted in a complete response in a CRPC patient with both a BRCA2 mutation and an MSI-high status.

一名同时具有 BRCA 阳性和高微卫星不稳定性的阉割耐药前列腺癌患者对 Pembrolizumab 完全应答:病例报告。
导言:在实体瘤癌症基因组检测中发现同时存在 BRCA 基因突变和微卫星不稳定性(MSI)高的患者很少见。据报道,13%的阉割耐药前列腺癌(CRPC)患者存在BRCA突变,3.1%的前列腺癌病例存在MSI-高/错配修复缺陷:一名有尿潴留病史的 71 岁男性因临床怀疑患有前列腺癌和前列腺特异性抗原(PSA)水平过高(141 ng/mL)而被转诊至我科。磁共振成像显示前列腺癌侵犯膀胱、精囊和直肠。前列腺经会阴穿刺活检标本的组织病理学检查显示为腺癌。骨闪烁成像显示有多处转移。患者接受了醋酸阿比特龙联合雄激素剥夺疗法,随后进行了局部放射治疗。同时还观察到直肠壁增厚和淋巴结转移,并使用了多西他赛。癌症基因小组检测结果显示 BRCA2 突变阳性,且 MSI 偏高。多西他赛治疗六个疗程后,观察到淋巴结肿大,于是开始使用奥拉帕尼。两个月后,转移病灶增大,PSA水平升高。随后,患者接受了 pembrolizumab 治疗。在开始使用 pembrolizumab 的 2 个月后,患者的 PSA 水平降至结论水平:我们在此报告了一个病例,在该病例中,Pembrolizumab 治疗使一名同时具有 BRCA2 突变和 MSI 高状态的 CRPC 患者获得了完全应答。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.40
自引率
12.50%
发文量
151
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信